Benjamin L. Ebert
- Cancer Research top 0.01%
- Cancer Genomics and Diagnostics 29
- Hematology top 0.01%
- Acute Myeloid Leukemia Research 126
- Multiple Myeloma Research and Treatments 20
- Genetics top 0.02%
- Myeloproliferative Neoplasms: Diagnosis and Treatment 64
- Molecular Biology top 0.01%
- Protein Degradation and Inhibitors 36
- RNA modifications and cancer 33
- Epigenetics and DNA Methylation 27
- Ubiquitin and proteasome pathways 24
- Immunology top 0.05%
- Co-authors
- Todd R. GolubPablo TamayoJill P. MesirovMichael A. GilletteAravind SubramanianEric S. LanderSayan MukherjeeScott L. Pomeroy
- Cited by
- Cancer ResearchHematologyGenetics
- Partner nations
- United StatesGermanySweden
In The Last Decade
Benjamin L. Ebert
286 papers receiving 72.7k citations
Hit Papers
Peers
Comparison fields: 5 of 203
- Cancer Research 19.4k
- Hematology 14.2k
- Genetics 9.0k
- Molecular Biology 46.7k
- Immunology 9.5k
Countries citing papers authored by Benjamin L. Ebert
This map shows the geographic impact of Benjamin L. Ebert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin L. Ebert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin L. Ebert more than expected).
Fields of papers citing papers by Benjamin L. Ebert
This network shows the impact of papers produced by Benjamin L. Ebert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin L. Ebert. The network helps show where Benjamin L. Ebert may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Benjamin L. Ebert, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 3 | |
| 2 | 2024 | 12 | |
| 3 | 2024 | 16 | |
| 4 | 2023 | 74 | |
| 5 | 2023 | 14 | |
| 6 | 2023 | 54 | |
| 7 | 2022 | 8 | |
| 8 | 2022 | 73 | |
| 9 | 2020 | 50 | |
| 10 | 2020 | 73 | |
| 11 | 2019 | 23 | |
| 12 | Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBNbreakdown → | 2018 | 341 |
| 13 | 2014 | 110 | |
| 14 | ( R )-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversiblebreakdown → | 2013 | 533 |
| 15 | Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cellsbreakdown → | 2013 | 1288 |
| 16 | 2013 | 126 | |
| 17 | Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cellsbreakdown → | 2013 | 3656 |
| 18 | 2012 | 312 | |
| 19 | 2010 | 38 | |
| 20 | 2010 | 9 |
About Benjamin L. Ebert
Benjamin L. Ebert is a scholar working on Hematology, Genetics and Cancer Research, having authored 294 papers that have together received 73.5k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (126 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (64 papers), Protein Degradation and Inhibitors (36 papers), RNA modifications and cancer (33 papers), Cancer Genomics and Diagnostics (29 papers), Epigenetics and DNA Methylation (27 papers), Ubiquitin and proteasome pathways (24 papers) and Multiple Myeloma Research and Treatments (20 papers). The work is most often cited by research in Cancer Research (19.4k citations), Hematology (14.2k citations) and Genetics (9.0k citations). Benjamin L. Ebert has collaborated with scholars based in United States, Germany and Sweden. Frequent co-authors include Todd R. Golub, Pablo Tamayo, Jill P. Mesirov, Michael A. Gillette, Aravind Subramanian, Eric S. Lander, Sayan Mukherjee, Scott L. Pomeroy, Amanda G. Paulovich and Vamsi K. Mootha. Their work appears in journals such as Blood, Leukemia, Blood Advances, Journal of Clinical Oncology and Circulation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.